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Mutations of the MEN1 gene, encoding the tumor suppressor menin, predispose individuals to the cancer
syndrome multiple endocrine neoplasia type 1, characterized by the development of tumors of the endocrine
pancreas and anterior pituitary and parathyroid glands. We have targeted the murine Men1 gene by using Cre
recombinase-loxP technology to develop both total and tissue-specific knockouts of the gene. Conditional
homozygous inactivation of the Men1 gene in the pituitary gland and endocrine pancreas bypasses the
embryonic lethality associated with a constitutional Men1/ genotype and leads to -cell hyperplasia in less
than 4 months and insulinomas and prolactinomas starting at 9 months. The pituitary gland and pancreas
develop normally in the conditional absence of menin, but loss of this transcriptional cofactor is sufficient to
cause -cell hyperplasia in some islets; however, such loss is not sufficient to initiate pituitary gland tumor-
igenesis, suggesting that additional genetic events are necessary for the latter.
The MEN1 tumor suppressor gene encodes the transcrip-
tional cofactor menin, and individuals with germ line-inacti-
vating mutations of this gene are predisposed to the cancer
syndrome multiple endocrine neoplasia type 1 (MEN 1) (6,
21). Mutation carriers develop hyperplasia and tumors primar-
ily of the endocrine pancreas and parathyroid and anterior
pituitary glands. Somatic mutations of the MEN1 gene are
commonly found in sporadic parathyroid tumors (13) and pan-
creatic tumors (35) but less frequently in pituitary tumors (36).
Highly conserved orthologs of the MEN1 gene have been
found in a variety of organisms, including molluscs (31), Dro-
sophila (11, 26), zebra fish (19, 25), rats (18), and mice (29).
However, the 610-amino-acid human menin sequence provides
few clues to the function of the protein, since it shows no
homology to any other protein and has no identifiable func-
tional motifs, except for two functionally independent, C-ter-
minal nuclear localization signals (12). The protein has a pre-
dominantly nuclear distribution through all stages of the cell
cycle (16, 32). Several menin-interacting partners have been
identified and include the transcription factors JunD (1),
Smad3 (17), NF-B (14), and Pem (22), suggesting a role for
menin in regulating gene expression. Additionally, a role for
menin in DNA repair has been implicated through its interac-
tion with the 32-kDa subunit (RPA2) of replication protein A
(30), as well as FANCD2, a protein defective in some patients
with Fanconi anemia (15).
Menin has been shown to repress the transcriptional activity
of JunD, and several mutations clustered around exon 3 inter-
fere with its binding to JunD (1). Further, suppression of
AP-1-mediated transcription appears to result from menin re-
ducing the induction of c-Fos expression (34) and inhibiting
c-Jun N-terminal kinase-mediated phosphorylation of both c-
Jun and JunD (9).
Menin is also necessary for the transcription of transforming
growth factor -responsive genes, an activity mediated through
a direct interaction of menin and Smad3 (17). While menin
does not influence Smad3-Smad4 dimerization or nuclear lo-
calization, it enhances Smad3 DNA binding and Smad3-medi-
ated transcriptional activation. The finding that menin is a key
regulator of growth-inhibitory signals arising from the activa-
tion of the transforming growth factor  pathway strongly
supports its role as a tumor suppressor.
To directly assess the tumor suppressor function of menin in
vivo, Crabtree and coworkers generated Men1 knockout mice
by deleting exons 3 to 8 of the gene (7). From 9 months of age,
heterozygous constitutional knockout mice (i.e., Men1/
mice) developed hyperplasia and tumors of the parathyroid
and anterior pituitary glands and pancreatic islets, the three
principal tissues affected in MEN 1. Other tumors normally
associated with MEN 1, such as adrenocortical carcinomas,
pheochromocytomas, gastric neuroendocrine tumors, and thy-
roid adenomas, were also observed, indicating that this mouse
model very closely mimics the human syndrome. Another mu-
rine model of MEN 1 has been developed by Bertolino et al.
(3); the mice display a very similar tumor spectrum but with the
addition of a high frequency of Leydig cell tumors in male mice
and ovary sex cord stromal tumors in female mice. Men1-null
mice die in utero at 10.5 to 12.5 days postcoitus (dpc), but the
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underlying cause of embryonic lethality has not been estab-
lished (2, 7). The embryos are developmentally delayed and
display a variety of abnormalities, including craniofacial de-
fects, cardiac hypotrophy, edema, hemorrhage, and failure of
neural tube closure.
To determine whether menin is essential for normal devel-
opment of the endocrine pancreas and to circumvent the em-
bryonic lethality of the Men1/ genotype, we sought to pro-
duce lines of mice in which the Men1 gene was deleted in a
tissue-specific manner in pancreatic  cells. To generate both
constitutional and tissue-specific knockouts of the Men1 gene,
exon 2 was selected for conditional deletion by the Cre recom-
binase-loxP system (28). When Cre recombinase is expressed
in cells carrying a loxP-flanked (floxed) allele, DNA between
the loxP recognition sites is deleted, generating a Men1/
genotype restricted to the target tissue. Cre-mediated deletion
of this exon removes the initiating methionine and approxi-
mately 20% of the coding sequence and results in a complete
loss of menin production, as determined by Western blot anal-
ysis (5). Mice with a constitutive deletion of exon 2 of the Men1
gene were generated by in vitro Cre treatment of embryonic
stem cells carrying the floxed allele prior to the establishment
of chimeras (5). Additionally, mice in which conditional inac-
tivation of the Men1 gene was specifically targeted to pancre-
atic  cells were generated by crossing mice homozygous for
the floxed allele (Men1loxP/loxP) with mice expressing a Cre
transgene under the control of the rat insulin II gene promoter
[TgN(Ins2cre)25Mgn, hereafter referred to as Rip-cre] (27).
MATERIALS AND METHODS
Targeting vector. The Men1 targeting construct, in which exon 2 was targeted
for deletion by Cre recombinase and hence flanked by loxP sites, was described
previously (5).
Mice. Chimeras generated from floxed Men1 exon 2 embryonic stem cells were
mated with C57BL/6J females, and pups were genotyped by PCR analysis as
described previously (5). Men1/loxP offspring were crossed with Rip-cre mice
(27), and the offspring were interbred with Men1loxP/loxP mice to generate con-
ditional Men1 knockout mice (Men1loxP/loxP Rip-cre) and littermate controls
(Men1loxP/loxP Rip-cre).
Mice expressing the Rip-cre transgene were crossed with the Z/AP Cre-ex-
pressing reporter strain [Tg(ACTB-Bgeo/ALPP)1Lbe] (where Z represents lacZ
and AP represents alkaline phosphatase) (23). Dually transgenic staged embryos
(i.e., Z/AP Rip-cre), adult offspring, and littermate controls (Z/AP Rip-cre)
were generated from mating of the respective singly transgenic mice.
All mice in the present study were treated in accordance with National Health
and Medical Research Council guidelines for the care of experimental animals.
Genotyping. Genomic DNA was extracted from a tail tip biopsy (or yolk sac)
by overnight digestion at 55°C in 0.7 ml (0.4 ml) of a solution containing 50 mM
Tris-HCl (pH 8.0), 20 mM EDTA (pH 8.0), 2.0% sodium dodecyl sulfate, and 0.5
mg of freshly added proteinase K/ml. Following salting out of proteins and
cellular debris with 0.25 ml of saturated NaCl, DNA was precipitated with 0.7 ml
of isopropanol. DNA pellets were washed with 70% ethanol, air dried, and
resuspended in 50 l of Tris-EDTA (pH 8.0) containing 1 l of RNase A (10
mg/ml).
PCR analysis was used to detect an approximately 500-bp PCR product of the
Rip-cre transgene with 2 l of a 1:30 dilution of tail tip DNA in a 25-l reaction
mixture containing the supplied reaction buffer (Fisher Biotech), 1.5 mM MgCl2,
2 mM deoxynucleoside triphosphate mixture, 1.4 U of F1 Taq polymerase (Fisher
Biotech), and 10 pmol each of primers Cre 3 (5 CAC CCT GTT ACG TAT
AGC 3) and Cre 4 (5 CTA ATC GCC ATC TTC CAG 3). PCR cycling
conditions were an initial denaturation step of 3 min at 94°C; 32 cycles of 30 s at
94°C, 30 s at 55°C, and 1 min at 72°C; and a final extension cycle of 5 min at 72°C.
Some remaining tail tissue was used for the detection of Z/AP transgene status
by staining with 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal) as
outlined by Lobe et al. (23).
Preparation of tissue and embryo samples and analysis of Rip-cre transgene
expression. Protocols for tissue and embryo preparation and staining for lacZ
and alkaline phosphatase (AP) activities were those outlined by Lobe et al. (23)
but with the following modifications. Embryos were stained for AP alone by using
the whole-mount protocol, sectioned, and counterstained with nuclear fast red
(NFR) for 30 to 60 s. Dual staining was assessed with adult tissues; following
nitroblue tetrazolium (NBT)–5-bromo-4-chloro-3-indolylphosphate (BCIP)
staining, frozen sections were washed with phosphate-buffered saline (PBS),
counterstained with NFR, and dehydrated through an ethanol-xylene series.
Immunohistochemical analysis. Formalin-fixed, paraffin-embedded sections
were used to detect hormone production in tumors. Sections were deparaffinized
and hydrated by passage through xylene and a graded ethanol series. For pitu-
itary tissue, endogenous peroxidase activity was quenched by incubating sections
with 3% aqueous hydrogen peroxide for 5 min and then washing with PBS (pH
7.6). Samples were incubated with rabbit anti-human prolactin polyclonal pri-
mary antibody (1:1,200 dilution; Dako A0569) or rabbit anti-human adrenocor-
ticotropin (ACTH) polyclonal primary antibody (1:3,500 dilution; Dako A0571)
for 30 min. After being washed with PBS, slides were incubated with a biotin-
conjugated anti-mouse or anti-rabbit immunoglobulin secondary antibody for 10
min, washed with PBS, incubated with peroxidase-conjugated streptavidin for 10
min, and washed with PBS. The chromogenic reaction was carried out with
3,3-diaminobenzidine (Dako K0675), yielding a brown product. Slides were
washed with water and then counterstained with hematoxylin. All incubations
were performed at room temperature, and all PBS washes were performed for 5
min.
Similarly, pancreatic tissues were stained for insulin but with the following
modifications. The primary antibody used was a guinea pig anti-swine insulin
polyclonal antibody (1:200 dilution; Dako A0564; 30 min), and the chromogen
used was 9-amino-3-ethylcarbazole (Dako K3461). All washes were performed
with 50 mM Tris-HCl (pH 7.6)– 0.05% Tween 20.
Proliferation assays. Assessment of the proliferation status of pancreatic islets
with and without expression of the Cre transgene was carried out by using
CDC47 (MCM7) immunohistochemical analysis. Sections of paraformaldehyde-
fixed, paraffin-embedded pancreatic tissues were incubated overnight with a
1:200 dilution of biotinylated anti-human CDC47/MCM7/Ab-2 (NeoMarkers;
MS-862), which specifically localizes to the nuclei of proliferating cells. This step
was followed by streptavidin-peroxidase (Jackson Laboratories) and 3,3-diami-
nobenzidine detection. Sections were lightly counterstained with Mayer’s hema-
toxylin. A proliferation index was calculated by counting proliferating cells
(brown nuclei) and nonproliferating cells (blue nuclei) in at least five islets from
each of three Cre and three littermate Cre animals.
Detection of Cre-mediated deletion of exon 2. For detecting conversion of the
floxed allele to the null allele, genomic DNA was isolated from formalin-fixed
tumor and normal tissue samples. Samples were coarsely chopped, suspended in
200 l of extraction buffer (50 mM Tris-HCl [pH 8.5], 0.5% [vol/vol] Tween 20,
0.4 mg of proteinase K/ml), and incubated at 55°C for 3 to 4 h; this process was
followed by overnight digestion at 37°C. Proteins were pelleted by the addition
of 0.25 volume of saturated NaCl solution and centrifugation at 1,500  g for 15
min. DNA was precipitated by the addition of 0.10 volume of 3 M sodium
acetate, 2.5 volumes of absolute ethanol, and glycogen to 20 g/ml, and samples
were placed at 20°C for 2 to 4 h. After centrifugation at 16,000  g for 20 min
at 4°C, pellets were washed with 70% ethanol, air dried, and resuspended in 20
l of Tris-EDTA.
DNA (1 l) from either tumor or normal tissue samples was used in a
multiplex genotyping PCR with a 25-l reaction mixture containing the supplied
reaction buffer (Fisher Biotech), 1.5 mM MgCl2, 2 mM deoxynucleoside triphos-
phate mixture, 1.4 U of F1 Taq polymerase, and 10 pmol each of primers 968F
(5 TTG GGA CTT GTG GGA GGC TG 3), 207R (5 AAG GAC AGG AGC
ACC AGG TC 3), and 2218R (5 CTC ACA AGA GGC CTC AGA TGC 3).
PCR cycling conditions were an initial denaturation step of 3 min at 95°C; 2
cycles of 1 min at 95°C, 1 min at 68°C, and 1 min at 72°C; 2 cycles of 1 min at
95°C, 1 min at 66°C, and 1 min at 72°C; 24 cycles of 1 min at 95°C, 1 min at 64°C,
and 1 min at 72°C; and a final extension cycle of 5 min at 72°C. PCR products
were separated and visualized on a 2% agarose gel to detect both a 516-bp floxed
exon 2 product (primers 968F and 207R) and a 500-bp deleted exon 2 band
(primers 968F and 2218R).
RESULTS AND DISCUSSION
To assess the activity of the Rip-cre transgene and determine
its tissue specificity, both during embryogenesis and in adult-
hood, Rip-cre mice were crossed with the Z/AP reporter
strain (23). These mice ubiquitously express a floxed lacZ gene
3126 BIONDI ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
in the absence of the Cre enzyme. In Cre-expressing cells, the
enzyme excises this portion of the transgene, allowing the
expression of the downstream human AP reporter gene and
resulting in a switch from blue staining (X-Gal staining for lacZ
activity) to purple staining (NBT-BCIP staining for AP activ-
ity). While Postic et al. (27) have shown that the Rip-cre trans-
gene is strongly expressed in  cells of the pancreas, we (this
study) and others (8, 10) have determined that Cre expression
driven by the Rip promoter is not restricted solely to  cells but
is found in a variety of other tissues of neuroendocrine lineage.
When the Z/AP reporter strain is used, Rip-cre transgene ex-
pression (AP staining) is detected as early as 8.5 dpc in Rath-
ke’s pouch (Fig. 1a), which develops to become the anterior
pituitary gland; by 11.5 dpc, it is also found in the diencephalon
and floor plate of the neural tube (Fig. 1b to d, f, and g). Some
cells stain in a region of the gut that corresponds to the posi-
tion of early pancreatic cell precursors (Fig. 1f). AP staining in
adult tissues is detected in pancreatic islets (Fig. 2b) and both
the anterior and the intermediate lobes of the pituitary gland
(Fig. 2f). Low levels are also found in a few regions of the
epididymis and thyroid gland and scattered throughout the
cerebral hemispheres of the brain (data not shown).
To assess endocrine organ development and tumorigenesis
in Men1loxP/loxP/Rip-cre mice, a cohort of animals that were
approximately 12 months old (n  21; median age, 12 months;
range, 4 to 16 months) was examined by full necropsy. All of
the mice had developed prominent hyperplasia of multiple
islets (Fig. 3a), and seven animals also had developed islet cell
tumors (Fig. 3e and f). Generally, tumor development oc-
curred earlier and was more severe (larger tumors and/or a
larger number of foci) in Men1loxP/loxP/Rip-cre mice than in
our line of Men1/ mice, which had developed a tumor spec-
trum very similar to that reported by others (3, 7) (data not
shown). Hyperplastic islets and islet cell tumors were stained
positively for insulin in all six samples examined (Fig. 3c, g, and
h).
After we had submitted the results of this study for publi-
cation, two other groups reported -cell-specific deletion of
the Men1 gene in mice (4, 8). The timing of islet hyperplasia
and insulinoma formation observed in our mice mirrors their
findings. Both of the other studies showed that insulinoma
development corresponded to an increase in serum insulin
levels and a concomitant decrease in blood glucose concentra-
tions. Although we did not measure these parameters in our
mice, we would expect similar changes to have occurred as a
direct consequence of the observed -cell hyperplasia.
Fifteen of the Men1loxP/loxP/Rip-cre mice (5 males and 10
females) developed adenomas of the anterior pituitary gland
FIG. 1. Cre recombinase expression in Z/AP/Rip-cre embryos. (a and b) AP whole-mount staining of Z/AP/Rip-cre embryos (right) and
Z/AP/Rip-cre littermates (left). (a) Embryo at 8.5 dpc showing Cre expression (purple AP staining) in the region of Rathke’s pouch (arrow).
(b) Embryo at 11.5 dpc showing scattered staining of cells in the lower dorsal region of the embryo and the vagal (X) and accessory (XI) cranial
nerve trunk (arrow). (c to g) Sections from 11.5-dpc embryos stained with AP as whole mounts (as above). Sections were counterstained with NFR.
(c and d) Z/AP/Rip-cre embryos showing AP staining (magnification, 40). (e) Z/AP/Rip-cre littermate control. (f and g) Z/AP/Rip-cre
embryos (magnification, 100) showing AP staining in the pituitary primordium, i.e., Rathke’s pouch (rp), the diencephalon (di), the floor plate
of the neural tube (nt), and scattered cells which may correspond to pancreatic precursor cells (pa). Liver (li), heart (he), and other tissues are
not stained by AP.
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(Fig. 4a and b). All six pituitary adenomas examined were
stained positively for prolactin (Fig. 4c and d) and were neg-
ative for growth hormone, ACTH, thyroid-stimulating hor-
mone, follicle-stimulating hormone, and luteinizing hormone.
The predominance of prolactinomas in these mice is consistent
with the human MEN 1 syndrome, in which these are the most
commonly seen pituitary lesions. None of the Men1loxP/loxP/Rip-
cre littermate controls examined (n  22; median age, 17
months; range, 4 to 25 months) had pancreatic or pituitary
abnormalities.
Surprisingly, in neither of the other models of Rip-cre trans-
gene-mediated conditional deletion of the Men1 gene were
pituitary lesions reported (4, 8), in stark contrast to our own
observations, where the majority of animals developed pro-
lactinomas. It is difficult to envisage that these differences
could have arisen through the alternative regions of the Men1
gene that were targeted for deletion in each of the studies
(exons 3 to 8 [8], exon 3 [4], and exon 2 [this study]). It is more
likely that the variations in phenotype were due to subtle
differences in the founder line carrying the Rip-cre transgene,
giving rise to subtle differences in the tissue distribution of Cre
expression.
While Z/AP analysis in our mice indicated that the Rip-cre
transgene was expressed in the intermediate lobe of the pitu-
itary gland, which in mice produces ACTH (24), only one
intermediate lobe adenoma was observed in Men1loxP/loxP/Rip-
cre mice. However, two other animals did show enlargement
of this tissue, confirmed by ACTH immunostaining in one (Fig.
4e and f). No intermediate lobe abnormalities were observed
in Men1loxP/loxP/Rip-cre animals. This finding is consistent
with the observed expression of the Rip-cre transgene in the
pars intermedia (Fig. 2f) and suggests that deletion of the
Men1 gene alone in this part of the pituitary gland has a more
FIG. 2. Detection of Cre-mediated excision. Pancreatic and pitu-
itary tissues (magnification, 400) from Z/AP/Rip-cre (a, b, e, and
f) and Z/AP/Rip-cre (c, d, g, and h) mice were examined. Tissues
stained with X-Gal and AP are indicated by blue staining and purple
staining, respectively. Hematoxylin and eosin staining of parallel sec-
tions for all tissues is shown in panels a, c, e, and g. (b) Islet cells
showing mosaic expression of the lacZ reporter gene. Cre excision is
indicated by AP staining. X-Gal staining is present in surrounding
acinar cells. (d) Pancreatic section showing expression of the lacZ
reporter transgene only. is, islet cells; ac, acinar cells. (f) Pituitary
section showing extensive Cre activity (AP staining) in the pars distalis
(p.d.) and pars intermedia (p.i.). Note that only lacZ expression is
faintly detected in the pars nervosa (p.n.). (h) Pituitary section coun-
terstained with NFR and showing expression of the lacZ reporter
transgene only.
FIG. 3. Pancreatic -cell hyperplasia and insulinoma in Men1loxP/loxP/
Rip-cre mice. (a to d) -Cell hyperplasia in a 4-month-old Men1loxP/loxP/
Rip-cre mouse (a and c) compared to a Men1loxP/loxP/Rip-cre littermate
(b and d). Staining was done with hematoxylin and eosin (H&E) (a and b;
magnification,20) and with a horseradish peroxidase-conjugated mouse
anti-insulin antibody (c and d; magnification, 20) (brown). (e to h)
Pancreatic islet cell tumor and islet cell hyperplasia in a Men1loxP/loxP/Rip-
cre mouse. Staining was done with H&E (e and f; magnifications, 20
and 200, respectively). Immunoperoxidase staining (brown) of islet cell
lesions was done with a mouse anti-insulin antibody (g and h; magnifica-
tions, 20 and 200, respectively).
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limited, although appreciable, effect in promoting neoplasia.
This finding contrasts markedly with the effect of deletion of
the Rb1 gene in this tissue, since up to 100% of Rb1/ mice
in some studies developed intermediate lobe tumors (33), and
is indicative of a general action of menin as a tumor suppres-
sor, even in tissues not normally associated with MEN 1.
Histological changes similar to the changes normally ob-
served during late pregnancy were observed in the mammary
tissue of two virgin female mice with pituitary adenomas.
These are likely to have been caused by endocrine action of
tumor-derived prolactin on the gland rather than to have been
a consequence of deletion of the Men1 gene in the mammary
tissue. Similarly, another incidental finding was observed in the
lung tissue from a female mouse: several pulmonary blood
vessels showed marked thickening of the smooth muscle layer
and narrowing of the lumen suggestive of pulmonary hyper-
tension. The vascular smooth muscle proliferation is likely to
have been induced by factors secreted by the pancreatic islet
cell tumor in this animal. A similar phenomenon occurs in
carcinoid syndrome, in which molecules (especially serotonin)
produced by intestinal neuroendocrine tumor cells cause en-
docardial fibrosis of the right side of the heart and lead to
systemic symptoms, such as flushing and diarrhea.
Histological analysis of tissues at an earlier age (i.e., 4
months) showed normal pituitary development. In pancreatic
tissue, mild to moderate islet cell hyperplasia was detected in
some islets, although the majority appeared normal. These
observations suggest that both of these tissues develop nor-
mally in the absence of menin. They also indicate that a com-
plete lack of menin is sufficient to initiate hyperplasia of  cells
but not the cells of the anterior pituitary gland. This conclusion
is supported by the finding of a much lower frequency of
MEN1 gene mutations in pituitary tumors (36) than in tumors
of the endocrine pancreas (20, 35) and suggests that other
genetic events are necessary to initiate pituitary tumorigenesis,
even in patients with MEN 1.
To determine whether the early islet cell hyperplasia was
associated with increased proliferation in  cells lacking me-
nin, we counted MCM7-stained proliferating nuclei in islets
from mice with and without conditional deletion of the Men1
gene. In a total of 28 wild-type islets from three mice, the
median proliferation index was 0 (range, 0 to 3). This index was
significantly lower (the P value, determined by the Mann-
Whitney U test, was 	0.0003) than the median of 2.5 (range,
0 to 22) found in 25 islets of comparable sizes from three
Men1loxP/loxP/Rip-cre mice. The latter was also significantly
lower (P value, 	0.0007) than the median of 48.8 (range, 22 to
51) found in three small pancreatic adenomas in mice with
-cell-specific deletion of the Men1 gene. Representative ex-
amples of islets and tumors from the mice are shown in Fig. 5.
We also attempted to determine whether the observed -cell
hyperplasia also might have been due in part to a lower degree
FIG. 4. Prolactinoma and hyperplasia of the pars intermedia in the
pituitary glands of Men1loxP/loxP/Rip-cre mice. (a and b) Adenoma (ad)
of anterior pituitary gland (pars distalis) stained with hematoxylin and
eosin (magnifications, 20 [a] and 400 [b]). (c and d) Immunoper-
oxidase staining (brown) of adenoma cells with a rabbit antiprolactin
polyclonal antibody (magnifications, 20 [c] and 400 [d]). (e and f)
Immunoperoxidase staining of the pars intermedia with a rabbit anti-
ACTH polyclonal antibody in a Men1loxP/loxP/Rip-cre mouse (e) and a
Men1loxP/loxP/Rip-cre littermate (f) (magnification for both panels,
20).
FIG. 5. Comparison of proliferation rates in islets or tumors from wild-type and Men1loxP/loxP/Rip-cre mice. Anti-MCM7 was used to stain
proliferating nuclei in a normal nonproliferating islet from a wild-type mouse (a); a small, moderately proliferating islet from a Men1loxP/loxP;
Rip-cre mouse (b); and a highly proliferating tumor from a Men1loxP/loxP/Rip-cre mouse (c). Scale bars, 50 m.
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of apoptosis in Men1-null cells; however, we were unable to
assess this possibility, since all cells in all islets from both
wild-type and Men1loxP/loxP/Rip-cre mice showed positive
staining in an assay for terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick end labeling (TUNEL). This phe-
nomenon was restricted to the islets, since only an occasional
TUNEL-positive cell was seen in the surrounding exocrine
tissues of all animals (data not shown). This finding in pancre-
atic islets was observed in tissues that were placed in fixative
within 15 min of necropsy and most likely was due to the rapid
onset of autolysis specifically associated with these tissues.
To confirm that Cre-mediated deletion of exon 2 had oc-
curred in tumor cells but not in cells not expressing Cre, mul-
tiplex PCR analysis was performed with representative samples
of pancreatic and pituitary lesions to detect conversion of the
floxed Men1 allele to the allele with exon 2 deleted. Only the
band with exon 2 deleted was detected in tumor cells, while the
floxed Men1 allele remained intact in tissues not expressing
Cre (Fig. 6).
In summary, the generation of Men1loxP/loxP/Rip-cre mice
has succeeded in bypassing the embryonic lethality of the total
knockout while inactivating the Men1 gene in parts of the
pituitary gland and  cells of the pancreas. This model reca-
pitulates part of the human MEN 1 syndrome and indicates
that menin is not essential for the normal development of
either the pancreas or the pituitary gland. As predicted, when
both copies of the gene are inactivated during embryogenesis,
the onset of tumorigenesis occurs significantly earlier than in
Men1/ mice, where tumors occur only after somatic loss of
the wild-type allele. The development of hyperplasia at such a
young age suggests that at least in mice, the loss of both copies
of the Men1 gene is sufficient for the development of endocrine
pancreatic hyperplasia. In contrast, only
60% of the mice had
pituitary tumors by 12 months of age. These findings imply
divergent pathways for tumor development in these primary
MEN 1 target tissues, suggesting that other events, such as loss
or gain of function of additional mutations and/or altered cell
signaling through hormonal imbalances, are required for the
development of pituitary lesions. Men1loxP/loxP/Rip-cre mice
provide a unique opportunity to examine the relationship be-
tween the onset of pancreatic lesions and the onset of pituitary
lesions in the MEN 1 syndrome and will allow further analysis
of the different genetic pathways underlying the development
of these tumor types.
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